TScan Therapeutics, Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

TScan Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $10.33 million for the year ending 2025.

  • TScan Therapeutics, Inc. showed an increase of +266.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from TScan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), TScan Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 851.6%.
  • Historical annual values: Fiscal year 2025: $10.33 million | Fiscal year 2024: $2.82 million | Fiscal year 2023: $21.05 million | Fiscal year 2022: $13.54 million | Fiscal year 2021: $10.14 million | Fiscal year 2020: $1.09 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: